FDA Eliminates Clozapine REMS, Directing Manufacturers to Submit Formal Modification and Update Prescribing Information

Clozapine manufacturers face a defined regulatory action item: FDA has instructed all clozapine product holders to formally submit a REMS elimination modification and revise prescribing information, including removal of mandatory ANC reporting requirements. Effective February 24, 2025, FDA no longer expects prescribers, pharmacies, or patients to participate in the Clozapine REMS or to submit absolute neutrophil count results prior to dispensing.

The decision follows a multi-year reevaluation that included three concurrent studies: a Brigham and Women's Hospital analysis of clozapine utilization and ANC monitoring adherence, a Veterans Health Administration collaboration examining neutropenia incidence and severity, and a Sentinel System review of monitoring compliance. FDA's conclusion is that the REMS program is no longer necessary to ensure the benefit-risk balance for clozapine, despite the continued existence of severe neutropenia risk.

For regulatory affairs leads, the submission obligation is unambiguous. FDA has notified manufacturers that the Clozapine REMS must be eliminated and that prescribing information updates are required. Boxed Warnings covering severe neutropenia will remain in labeling across all approved clozapine products; the modification removes the mandatory reporting infrastructure, not the clinical risk communication. FDA has indicated it will work with manufacturers in the coming months to finalize both the labeling revisions and the formal REMS elimination.

QA and pharmacovigilance teams should note that ANC monitoring remains a clinical recommendation under the revised prescribing information, even without the REMS enforcement mechanism. The shift from a mandated shared-system registry to a labeling-based monitoring recommendation represents a structural change in how risk is communicated and tracked at the product level. Internal SOPs tied to REMS compliance workflows will require review against the updated 21 CFR Part 208 obligations once the formal modification is approved.

The precedent carries weight beyond clozapine: this marks one of the more significant REMS eliminations in recent years and signals that FDA's ongoing REMS review cycle can result in full program removal where real-world evidence supports a revised benefit-risk determination. Regulatory affairs teams at other manufacturers operating under shared-system REMS programs should monitor the clozapine modification submission process as a procedural reference point.

The measurable near-term checkpoint is the formal submission of the REMS elimination modification by clozapine manufacturers, with FDA's collaborative prescribing information update process expected to conclude within the months following the February 2025 announcement.

Source: FDA Drugs RSS Feed via fda.gov, February 24, 2025; advisory committee meeting held November 19, 2024.